Udenyca – Talk Bio

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals for $558.4 Million

5 months ago talkbio0Tagged Biosciences, Coherus, Dosage Forms, immuno-oncology, Intas, pegfilgrastim-cbqv, Udenyca

Coherus BioSciences, Udenyca, Intas Pharmaceuticals, pegfilgrastim-cbqv, immuno-oncology, pharmaceutical deal

Coherus Resumes Biosimilar Supply Following Temporary Disruption; Novavax Terminates COVID-19 Vaccine Deal with UK

6 months ago talkbio0Tagged Biosciences, Biosimilar Supply, Coherus, COVID19 (disease), Novavax, Supply chain issues, Udenyca, UK, Vaccines

Coherus BioSciences, Biosimilar supply, UDENYCA, Supply chain issues, Novavax, COVID-19 vaccine deal, UK

Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption

7 months ago talkbio0Tagged Biosciences, Biosimilars, Cancer Therapeutic Procedure, Coherus, Disruption, Neulasta, pegfilgrastim, Pharmaceutical Supply Chain, Udenyca, White Blood Cell Count procedure

UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.